Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-Intensity HSCT in Non-Malignant Disease
NCT00920972Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2001
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of alemtuzumab, fludarabine, melphalan, thiotepa, abatacept in non-malignant disorders, thalassemia, hemoglobinopathies, sponsored by Washington University School of Medicine. Started Dec 2001; status: recruiting.
02
Drugs
alemtuzumabfludarabinemelphalanthiotepaabatacept
03
Conditions
non-malignant disordersthalassemiahemoglobinopathies
Beyond the preview
Go deeper on NCT00920972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920972.